Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mazen S. Zenati"'
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Nathan Bahary, Mazen S. Zenati, M.E. Hogg, Asmita Chopra, Herbert J. Zeh, David L. Bartlett, Joal D. Beane, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 28:7759-7769
A positive microscopic margin (R1) following resection of pancreatic ductal adenocarcinoma (PDAC) can occur in up to 80% of patients and is associated with reduced survival and increased recurrence. Our aim was to characterize the impact of neoadjuva
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Autor:
Caroline J. Rieser, David L. Bartlett, Asmita Chopra, Kenneth K.W. Lee, Sowmya Narayanan, Amer H. Zureikat, Alessandro Paniccia, Samer AlMasri, Tracy Daum, Mazen S. Zenati, Katelyn Smith, Nathan Bahary, Vivianne Oyefusi, Ibrahim Nassour
Publikováno v:
J Surg Oncol
BACKGROUND AND OBJECTIVES Neoadjuvant chemotherapy (NAT) for pancreatic adenocarcinoma (PDAC) is increasingly being utilized. However, a significant number of patients will experience early recurrence, possibly negating the benefit of surgery. We aim
Autor:
Amer H. Zureikat, David L Bartlett, Kenneth K. Lee, Mazen S. Zenati, Nathan Bahary, Alessandro Paniccia, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
Ann Surg Oncol
Neoadjuvant therapy (NAT) is a growing strategy for patients with resectable pancreatic ductal adenocarcinoma (PDAC). Elderly patients are at increased risk of treatment withdrawal due to functional decline, and the benefit of NAT in this cohort rema
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3263486cc36ea0870e151d9eee750612
https://europepmc.org/articles/PMC8614241/
https://europepmc.org/articles/PMC8614241/
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Alessandro Paniccia, Samer AlMasri, Mohammed Aldakkak, Mazen S. Zenati, Susannah G. Ellsworth, Douglas B. Evans, Kenneth K. Lee, Amer H. Zureikat, A.Y. Hammad, Aatur D. Singhi, Susan Tsai
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S145
PURPOSE/OBJECTIVE(S) Loss of the tumor suppressor gene SMAD4 is a critical genetic alteration in pancreatic carcinoma (PC). We hypothesized that SMAD4 status in PC is associated with outcomes in patients who received neoadjuvant (NARx) or adjuvant (A
Autor:
Nathan Bahary, Caroline J. Rieser, Herbert J. Zeh, Mazen S. Zenati, Kenneth K. Lee, Amer H. Zureikat, Hao Liu, Aatur D. Singhi, Amr Al-abbas, Melissa E. Hogg
Publikováno v:
Ann Surg Oncol
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly utilized for pancreatic cancer, however the added benefit of adjuvant therapy (AT) in this setting is unknown. We hypothesized that the magnitude of CA19-9 response to NAT can guide the need for f
Autor:
Virginia Falvello, Nathan Bahary, Herbert J. Zeh, Amer H. Zureikat, Ashika Mani, Mazen S. Zenati, Amr I. Al Abbas, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Journal of surgical oncologyREFERENCES.
BACKGROUND AND OBJECTIVES Ampullary adenocarcinoma (AA) is classified by immunohistochemical (IHC) subtypes into intestinal (IN), pancreatobiliary (PB), and ambiguous (AM). The impact of adjuvant therapy on IHC subtype and disease stage is unclear. W